Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the Chairman of the Board, Michael Wolff Jensen, has informed the company that he will not stand for re-election at the 2021 Annual General Meeting (AGM).
Michael Wolff Jensen has been Chairman of Xspray Pharma’s Board of Directors since 2013, and will stay as Chairman until the upcoming AGM, scheduled to May 20, 2021. Michael Wolff Jensen informed the company well ahead of the AGM 2021 allowing the nomination committee to initiate their work of finding a new chairman. Xspray’s nomination committee will, after its formation in October, start their work to find a successor to Michael Wolff Jensen.
“I have truly enjoyed working for Xspray, on the Board, as well as with Per Andersson, and I am proud to hand over a company in great condition to the next chairman. It is time for me to re-balance my time spent professionally and privately and I want to announce well ahead of the AGM that I will not be available for a next term in order for the nomination committee to find the best possible chairman candidate. Before I hand over to the next Chairman, I will focus on progressing our extensive efforts in finding a commercial partner for HyNap-Dasa”, comments Michael Wolff Jensen, Chairman of Xspray.
“It has been stimulating working with Michael Wolff Jensen for the last seven years,” comments Per Andersson, CEO of Xspray. “His knowledge and experience from building life science companies has been of great value to Xspray and I would like to thank him for his support and dedication. Seven years ago Xspray was a private early-stage preclinical company, and with the implementation of a strategy focusing on development of PKI drugs, Xspray is now listed on Nasdaq Stockholm and has a late stage product pipeline and a market value over SEK 2 billion.”